Immuneering Corp (IMRX) Stock Price & Analysis

Immuneering Corp (IMRX) fell 4.37% to USD 4.82 as of September 8, 2026 at 06:23 UTC, according to Nexqual real-time market data.

IMRX last closed at USD 4.82; the session ranged USD 4.81–5 on volume of 1,000,331 shares. Market capitalization is —, with a 52-week range of USD 3.86–10.08 (NGM). Source: Nexqual, September 8, 2026 at 06:23 UTC.

Key Statistics (as of September 8, 2026 at 06:23 UTC)

Technical Analysis (IMRX)

Nexqual's technical model rates IMRX "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:23 UTC.

From Immuneering Corp's Latest SEC 10-K Filing (filed 2026-03-06)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data to generate insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views.
• Over time, we have developed a proprietary technology platform to facilitate that process and, in early 2018, we began applying the extensive counterintuitive insights from and capabilities of our platform and approach to create a wholly owned pipeline of novel small molecule drug programs, initially focusing on oncology.
• Overview Our DCI platform is enabled by two key elements: • Bioinformatics: our ability to efficiently analyze high-throughput molecular-level biochemical assays, including transcriptomics, genomics and/or proteomics, collectively referred to as Omics data; and • 3D Tumor Modeling: our ability to conduct in vitro studies in our own labs using proprietary humanized 3D tumor growth assays that we believe predict in vivo activity more accurately than traditional 2D cell culture models.
• We began applying our proprietary platform and approach to internally develop our wholly owned pipeline of Deep Cyclic Inhibitors, orally administered small molecule drug programs.

Partnerships

• These different types of biochemical and 3D tumor growth assays each provide us with unique information about the molecular mechanisms of disease biology and drug response and help to guide our translational planning and development. 7 Table of Contents Since our inception, we have partnered with industry-leading pharmaceutical and biotechnology companies to perform a variety of analyses that utilize our expertise in translational bioinformatics.
• In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clinical trial of patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed on prior therapy.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:23 UTC. This page is informational and not investment advice.